The role of image-guided therapy in the management of colorectal cancer metastatic disease

European Journal of Cancer

Volumn 75, Issue , 2017, Pages 231-242

  de Baere, Thierry ^a   Tselikas, Lambros ^a   Yevich, Steven ^a   Boige, Valérie ^a   Deschamps, Frederic ^a   Ducreux, Michel ^a   Goere, Diane ^a   Nguyen, France ^a   Malka, David ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Colorectal cancer; Hepatic arterial infusion; Image guided; Metastases; Radioembolisation; Radiofrequency; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT;

BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOEMBOLIZATION; HEPATIC ARTERY; HUMAN; INTERVENTIONAL RADIOLOGY; LUNG METASTASIS; META ANALYSIS (TOPIC); METASTATIC COLORECTAL CANCER; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR ABLATION; BONE NEOPLASMS; BRACHYTHERAPY; CATHETER ABLATION; COLORECTAL TUMOR; COMPUTER ASSISTED SURGERY; FORECASTING; IMAGE GUIDED RADIOTHERAPY; LIVER NEOPLASMS; LUNG NEOPLASMS; PROCEDURES; REGIONAL PERFUSION; SECONDARY;

BONE NEOPLASMS; BRACHYTHERAPY; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; FORECASTING; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; RADIOTHERAPY, IMAGE-GUIDED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURGERY, COMPUTER-ASSISTED;

EID: 85013633290     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.01.010     Document Type: Review

References (102)

1. [1] Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., Aderka, D., et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:8 (2016), 1386–1422.
2. [2] Goldberg, S.N., Gazelle, G.S., Solbiati, L., Rittman, W.J., Mueller, P.R., Radiofrequency tissue ablation: increased lesion diameter with a perfusion electrode. Acad Radiol 3 (1996), 636–644.
3. [3] Gage, A.A., Baust, J.M., Baust, J.G., Experimental cryosurgery investigations in vivo. Cryobiology 59:3 (2009), 229–243.
4. [4] Wright, A.S., Sampson, L.A., Warner, T.F., Mahvi, D.M., Lee, F.T. Jr., Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology 236:1 (2005), 132–139.
5. [5] Dodd, G.D. 3rd, Dodd, N.A., Lanctot, A.C., Glueck, D.A., Effect of variation of portal venous blood flow on radiofrequency and microwave ablations in a blood-perfused bovine liver model. Radiology 267:1 (2013), 129–136.
6. [6] Elias, D., Baton, O., Sideris, L., Matsuhisa, T., Pocard, M., Lasser, P., Local recurrences after intraoperative radiofrequency ablation of liver metastases: a comparative study with anatomic and wedge resections. Ann Surg Oncol 11:5 (2004), 500–505.
7. [7] Nielsen, K., van Tilborg, A.A., Meijerink, M.R., Macintosh, M.O., Zonderhuis, B.M., de Lange, E.S., et al. Incidence and treatment of local site recurrences following RFA of colorectal liver metastases. World J Surg 37:6 (2013), 1340–1347.
8. [8] Wang, X., Sofocleous, C.T., Erinjeri, J.P., Petre, E.N., Gonen, M., Do, K.G., et al. Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Interv Radiol 36:1 (2013), 166–175.
9. [9] Denys, A.L., De Baere, T., Kuoch, V., Dupas, B., Chevallier, P., Madoff, D.C., et al. Radio-frequency tissue ablation of the liver: in vivo and ex vivo experiments with four different systems. Eur Radiol 13:10 (2003), 2346–2352.
10. [10] Elias, D., De Baere, T., Smayra, T., Ouellet, J.F., Roche, A., Lasser, P., Percutaneous radiofrequency thermoablation as an alternative to surgery for treatment of liver tumour recurrence after hepatectomy. Br J Surg 89:6 (2002), 752–756.
11. [11] Gillams, A., Khan, Z., Osborn, P., Lees, W., Survival after radiofrequency ablation in 122 patients with inoperable colorectal lung metastases. Cardiovasc Interv Radiol 36:3 (2013 Jun), 724–730, 10.1007/s00270-012-0500-3 [Epub 2012 Oct 17].
12. [12] de Baere, T., Deschamps, F., Briggs, P., Dromain, C., Boige, V., Hechelhammer, L., et al. Hepatic malignancies: percutaneous radiofrequency ablation during percutaneous portal or hepatic vein occlusion. Radiology 248:3 (2008), 1056–1066.
13. [13] Sofocleous, C.T., Petre, E.N., Gonen, M., Brown, K.T., Solomon, S.B., Covey, A.M., et al. CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy. J Vasc Interv Radiol 22:6 (2011), 755–761.
14. [14] Ruers, T., Punt, C., Van Coevorden, F., Pierie, J.P., Borel-Rinkes, I., Ledermann, J.A., et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 23:10 (2012), 2619–2626.
15. [15] Primrose, J., Falk, S., Finch-Jones, M., Valle, J., O'Reilly, D., Siriwardena, A., et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the new EPOC randomised controlled trial. Lancet Oncol 15:6 (2014), 601–611.
16. [16] Tanis, E., Nordlinger, B., Mauer, M., Sorbye, H., van Coevorden, F., Gruenberger, T., et al. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer 50:5 (2014), 912–919.
17. [17] Nishiwada, S., Ko, S., Mukogawa, T., Ishikawa, H., Matsusaka, M., Nakatani, T., et al. Comparison between percutaneous radiofrequency ablation and surgical hepatectomy focusing on local disease control rate for colorectal liver metastases. Hepatogastroenterology 61:130 (2014), 436–441.
18. [18] Vigano, L., Capussotti, L., Lapointe, R., Barroso, E., Hubert, C., Giuliante, F., et al. Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6025 patients. Ann Surg Oncol 21:4 (2014), 1276–1286.
19. [19] Abdalla, E.K., Vauthey, J.N., Ellis, L.M., Ellis, V., Pollock, R., Broglio, K.R., et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:6 (2004), 818–825.
20. [20] Berber, E., Tsinberg, M., Tellioglu, G., Simpfendorfer, C.H., Siperstein, A.E., Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg 12:11 (2008), 1967–1972.
21. [21] Wu, Y.Z., Li, B., Wang, T., Wang, S.J., Zhou, Y.M., Radiofrequency ablation vs hepatic resection for solitary colorectal liver metastasis: a meta-analysis. World J Gastroenterol 17:36 (2011), 4143–4148.
22. [22] Cirocchi, R., Trastulli, S., Boselli, C., Montedori, A., Cavaliere, D., Parisi, A., et al. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database Syst Rev, 6, 2012, CD006317.
23. [23] Hammill, C.W., Billingsley, K.G., Cassera, M.A., Wolf, R.F., Ujiki, M.B., Hansen, P.D., Outcome after laparoscopic radiofrequency ablation of technically resectable colorectal liver metastases. Ann Surg Oncol 18:7 (2011), 1947–1954.
24. [24] Karanicolas, P.J., Jarnagin, W.R., Gonen, M., Tuorto, S., Allen, P.J., Dematteo, R.P., et al. Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases. JAMA Surg 148:7 (2013), 597–601.
25. [25] Eltawil, K.M., Boame, N., Mimeault, R., Shabana, W., Balaa, F.K., Jonker, D.J., et al. Patterns of recurrence following selective intraoperative radiofrequency ablation as an adjunct to hepatic resection for colorectal liver metastases. J Surg Oncol 110:6 (2014), 734–738.
26. [26] Ruers, T.J., Punt, C.J.A., van Coevorden, F., Pierie, J.P., Borel Rinkes, I.H., Ledermann, J.A., et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). J Clin Oncol, 33(Suppl), 2015 abstr 3501.
27. [27] Ahmed, M., Liu, Z., Afzal, K.S., Weeks, D., Lobo, S.M., Kruskal, J.B., et al. Radiofrequency ablation: effect of surrounding tissue composition on coagulation necrosis in a canine tumor model. Radiology 230:3 (2004), 761–767.
28. [28] de Baere, T., Auperin, A., Deschamps, F., Chevallier, P., Gaubert, Y., Boige, V., et al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol 26:5 (2015 May), 987–991, 10.1093/annonc/mdv037 [Epub 2015 Feb 16].
29. [29] Chua, T.C., Sarkar, A., Saxena, A., Glenn, D., Zhao, J., Morris, D.L., Long-term outcome of image-guided percutaneous radiofrequency ablation of lung metastases: an open-labeled prospective trial of 148 patients. Ann Oncol 21:10 (2010), 2017–2022.
30. [30] Gillams, A., Khan, Z., Osborn, P., Lees, W., Survival after radiofrequency ablation in 122 patients with inoperable colorectal lung metastases. Cardiovasc Interv Radiol 36:3 (2013), 724–730.
31. [31] Hamada, A., Yamakado, K., Nakatsuka, A., Uraki, J., Kashima, M., Takaki, H., et al. Radiofrequency ablation for colorectal liver metastases: prognostic factors in non-surgical candidates. Jpn J Radiol 30:7 (2012), 567–574.
32. [32] Iida, T., Nomori, H., Shiba, M., Nakajima, J., Okumura, S., Horio, H., et al. Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: a retrospective analysis. Ann Surg 257:6 (2013 Jun), 1059–1064, 10.1097/SLA.0b013e31826eda3b.
33. [33] Gonzalez, M., Poncet, A., Combescure, C., Robert, J., Ris, H.B., Gervaz, P., Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol 20:2 (2013), 572–579.
34. [34] Pfannschmidt, J., Hoffmann, H., Dienemann, H., Reported outcome factors for pulmonary resection in metastatic colorectal cancer. J Thorac Oncol 5:6 Suppl. 2 (2010), S172–S178.
35. [35] Pastorino, U., McCormack, P.M., Ginsberg, R.J., A new staging proposal for pulmonary metastases. The results of analysis of 5206 cases of resected pulmonary metastases. Chest Surg Clin N Am 8:1 (1998), 197–202.
36. [36] von Meyenfeldt, E.M., Wouters, M.W., Fat, N.L., Prevoo, W., Burgers, S.A., van Sandick, J.W., et al. Local treatment of pulmonary metastases: from open resection to minimally invasive approach? Less morbidity, comparable local control. Surg Endosc 26:8 (2012), 2312–2321.
37. [37] Dominguez-Ventura, A., Nichols, F.C. 3rd, Lymphadenectomy in metastasectomy. Thorac Surg Clin 16:2 (2006), 139–143.
38. [38] Inoue, M., Ohta, M., Iuchi, K., Matsumura, A., Ideguchi, K., Yasumitsu, T., et al. Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 78:1 (2004), 238–244.
39. [39] Jaskolka, J.D., Kachura, J.R., Hwang, D.M., Tsao, M.S., Waddell, T.K., Asch, M.R., et al. Pathologic assessment of radiofrequency ablation of pulmonary metastases. J Vasc Interv Radiol 21:11 (2010), 1689–1696.
40. [40] de Baere, T., Palussiere, J., Auperin, A., Hakime, A., Abdel-Rehim, M., Kind, M., et al. Mid-term local efficacy and survival after radiofrequency ablation of lung tumors with a minimum follow-up of 1 year: prospective evaluation. Radiology 240 (2006), 587–596.
41. [41] Lencioni, R., Crocetti, L., Cioni, R., Suh, R., Glenn, D., Regge, D., et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol 9:7 (2008), 621–628.
42. [42] Ensminger, W.D., Rosowsky, A., Raso, V., Levin, D.C., Glode, M., Come, S., et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res 38:11 Pt 1 (1978), 3784–3792.
43. [43] Allen-Mersh, T.G., Earlam, S., Fordy, C., Abrams, K., Houghton, J., Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344:8932 (1994), 1255–1260.
44. [44] Rougier, P., Laplanche, A., Huguier, M., Hay, J.M., Ollivier, J.M., Escat, J., et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 10:7 (1992), 1112–1118.
45. [45] Kemeny, N.E., Melendez, F.D., Capanu, M., Paty, P.B., Fong, Y., Schwartz, L.H., et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 27:21 (2009), 3465–3471.
46. [46] Boige, V., Malka, D., Elias, D., Castaing, M., De Baere, T., Goere, D., et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 15:1 (2008), 219–226.
47. [47] Malka, D., Paris, E., Caramella, C., Guimbaud, R., De Baere, T., Elias, D., et al. Combined hepatic oxaliplatin, intravenous LV5FU2 and Erbitux. Proc ASCO, 2010, 2010 abstr 3558.
48. [48] Allard, M.A., Sebagh, M., Baillie, G., Lemoine, A., Dartigues, P., Faitot, F., et al. Comparison of complete pathologic response and hepatic injuries between hepatic arterial infusion and systemic administration of oxaliplatin in patients with colorectal liver metastases. Ann Surg Oncol 22:6 (2015), 1925–1932, 10.1245/s10434-014-4272-7 [Epub 2014 Dec 2].
49. [49] Levi, F.A., Boige, V., Hebbar, M., Smith, D., Lepere, C., Focan, C., et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol 27:2 (2016), 267–274.
50. [50] Bouchahda, M., Boige, V., Smith, D., Karaboue, A., Ducreux, M., Hebbar, M., et al. Early tumour response as a survival predictor in previously-treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. Eur J Cancer 68 (2016), 163–172.
51. [51] Deschamps, F., Rao, P., Teriitehau, C., Hakime, A., Malka, D., Boige, V., et al. Percutaneous femoral implantation of an arterial port catheter for intraarterial chemotherapy: feasibility and predictive factors of long-term functionality. J Vasc Interv Radiol 21:11 (2010), 1681–1688.
52. [52] Tajima, T., Yoshimitsu, K., Kuroiwa, T., Ishibashi, T., Irie, H., Aibe, H., et al. Percutaneous femoral catheter placement for long-term chemotherapy infusions: preliminary technical results. AJR Am J Roentgenol 184:3 (2005), 906–914.
53. [53] Tanaka, T., Arai, Y., Inaba, Y., Matsueda, K., Aramaki, T., Takeuchi, Y., et al. Radiologic placement of side-hole catheter with tip fixation for hepatic arterial infusion chemotherapy. J Vasc Interv Radiol 14:1 (2003), 63–68.
54. [54] Hildebrandt, B., Pech, M., Nicolaou, A., Langrehr, J.M., Kurcz, J., Bartels, B., et al. Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: a phase II-study and historical comparison with the surgical approach. BMC Cancer, 7, 2007, 69.
55. [55] Deschamps, F., Elias, D., Goere, D., Malka, D., Ducreux, M., Boige, V., et al. Intra-arterial hepatic chemotherapy: a comparison of percutaneous versus surgical implantation of Port-Catheters. Cardiovasc Interv Radiol 34:5 (2011), 973–979.
56. [56] Benhaim, L., Goere, D., Deschamps, F., Dumont, F., Bonnet, S., Honore, C., et al. Placement of an arterial hepatic catheter after a major hepatectomy for colorectal liver metastases: is this safe?. Eur J Surg Oncol 39:6 (2013), 640–647.
57. [57] Farouil, G., Deschamps, F., Barah, A., Auperin, A., Goere, D., Elias, D., et al. Interventional revisions of malfunctions affecting surgically implanted port-catheters for hepatic artery infusion. Surg Oncol 22:1 (2013), 48–54.
58. [58] Kennedy, A., Nutting, C., Coldwell, D., Gaiser, J., Drachenberg, C., Pathologic response and microdosimetry of 90Y-microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 60 (2004), 1552–1563.
59. [59] Campbell, A., Bailey, I., Burton, M., Tumour dosimetry in human liver following hepatic 90Y-microsphere therapy. Phys Med Biol Phys Med Biol 46 (2001), 487–498.
60. [60] Dawson, L., McGinn, C., ormolle, D., Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 18 (2000), 2210–2218.
61. [61] van de Maat, G.H., Seevinck, P.R., Elschot, M., Smits, M.L., de Leeuw, H., van Het Schip, A.D., et al. MRI-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation. Eur Radiol 23:3 (2013), 827–835.
62. [62] Smits, M.L., Nijsen, J.F., van den Bosch, M.A., Lam, M.G., Vente, M.A., Mali, W.P., et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol 13:10 (2012), 1025–1034.
63. [63] Nicolay, N., Berry, D., Sharma, R., Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol 6:12 (2009), 687–697.
64. [64] Van Hazel, G., Blackwell, A., Anderson, J., Price, D., Moroz, P., Bower, G., et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88:2 (2004), 78–85.
65. [65] Sharma, R., Van Hazel, G.A., Morgan, B., Berry, D.P., Blanshard, K., Price, D., et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 25 (2007), 1099–1106.
66. [66] van Hazel, G.A., Pavlakis, N., Goldstein, D., Olver, I.N., Tapner, M.J., Price, D., et al. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol 27:25 (2009), 4089–4095.
67. [67] Gray, B., Van Hazel, G., Hope, M., Burton, M., Moroz, P., Anderson, J., et al. Randomised trial of SIR-spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12:12 (2001), 1711–1720.
68. [68] Mulcahy, M.F., Lewandowski, R.J., Ibrahim, S.M., Sato, K.T., Ryu, R.K., Atassi, B., et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 115:9 (2009), 1849–1858.
69. [69] Cosimelli, M., Golfieri, R., Cagol, P., Carpanese, L., Sciuto, R., Maini, C., et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 103:3 (2010), 324–331.
70. [70] Hendlisz, A., Van den Eynde, M., Peeters, M., Maleux, G., Lambert, B., Vannoote, J., et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 28:23 (2010), 3687–3694.
71. [71] Saxena, A., Meteling, B., Kapoor, J., Golani, S., Morris, D.L., Bester, L., Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients. Ann Surg Oncol 22:3 (2015), 794–802.
72. [72] Bester, L., Meteling, B., Pocock, N., Pavlakis, N., Chua, T.C., Saxena, A., et al. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol 23:1 (2012), 96–105.
73. [73] Kennedy, A.S., McNeillie, P., Dezarn, W.A., Nutting, C., Sangro, B., Wertman, D., et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 74:5 (2009), 1494–1500.
74. [74] Sangro, B., Gil-Alzugaray, B., Rodriguez, J., Sola, I., Martinez-Cuesta, A., Viudez, A., et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 112:7 (2008), 1538–1546.
75. [75] Garlipp, B., de Baere, T., Damm, R., Irmscher, R., van Buskirk, M., Stubs, P., et al. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. Hepatology 59:5 (2014), 1864–1873.
76. [76] Abbott, A.M., Kim, R., Hoffe, S.E., Arslan, B., Biebel, B., Choi, J., et al. Outcomes of therasphere radioembolization for colorectal metastases. Clin Colorectal Cancer 14:3 (2015 Sep), 146–153, 10.1016/j.clcc.2015.02.002 [Epub 2015 Feb 16].
77. [77] Dutton, S.J., Kenealy, N., Love, S.B., Wasan, H.S., Sharma, R.A., Group, F.P.D., et al. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. BMC Cancer, 14, 2014, 497.
78. [78] Rao, P.P., Pascale, F., Seck, A., Auperin, A., Drouard-Troalen, L., Deschamps, F., et al. Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model. Cardiovasc Interv Radiol 35:6 (2012), 1448–1459.
79. [79] Jordan, O., Denys, A., De Baere, T., Boulens, N., Doelker, E., Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan. J Vasc Interv Radiol 21:7 (2010), 1084–1090.
80. [80] Martin, R.C. 2nd, Scoggins, C.R., Tomalty, D., Schreeder, M., Metzger, T., Tatum, C., et al. Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. J Gastrointest Surg 16:8 (2012), 1531–1538.
81. [81] Fiorentini, G., Aliberti, C., Tilli, M., Mulazzani, L., Graziano, F., Giordani, P., et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 32:4 (2012), 1387–1395.
82. [82] Roth, E.S., Fetzer, D.T., Barron, B.J., Joseph, U.A., Gayed, I.W., Wan, D.Q., Does colon cancer ever metastasize to bone first? A temporal analysis of colorectal cancer progression. BMC Cancer, 9, 2009, 274.
83. [83] Santini, D., Tampellini, M., Vincenzi, B., Ibrahim, T., Ortega, C., Virzi, V., et al. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol 23:8 (2012), 2072–2077.
84. [84] Portales, F., Thezenas, S., Samalin, E., Assenat, E., Mazard, T., Ychou, M., Bone metastases in gastrointestinal cancer. Clin Exp Metastasis 32:1 (2015), 7–14.
85. [85] Coleman, R.E., Skeletal complications of malignancy. Cancer 80:8 Suppl. (1997), 1588–1594.
86. [86] Kashima, M., Yamakado, K., Takaki, H., Kaminou, T., Tanigawa, N., Nakatsuka, A., et al. Radiofrequency ablation for the treatment of bone metastases from hepatocellular carcinoma. AJR Am J Roentgenol 194:2 (2010), 536–541.
87. [87] Goetz, M.P., Callstrom, M.R., Charboneau, J.W., Farrell, M.A., Maus, T.P., Welch, T.J., et al. Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol 22:2 (2004), 300–306.
88. [88] Thanos, L., Mylona, S., Galani, P., Tzavoulis, D., Kalioras, V., Tanteles, S., et al. Radiofrequency ablation of osseous metastases for the palliation of pain. Skelet Radiol 37:3 (2008), 189–194.
89. [89] Deschamps, F., Farouil, G., de Baere, T., Percutaneous ablation of bone tumors. Diagn Interv Imaging 95:7–8 (2014), 659–663.
90. [90] Botton, E., Edeline, J., Rolland, Y., Vauleon, E., Le Roux, C., Mesbah, H., et al. Cementoplasty for painful bone metastases: a series of 42 cases. Med Oncol 29:2 (2012), 1378–1383.
91. [91] Alvarez, L., Perez-Higueras, A., Quinones, D., Calvo, E., Rossi, R.E., Vertebroplasty in the treatment of vertebral tumors: postprocedural outcome and quality of life. Eur Spine J 12:4 (2003), 356–360.
92. [92] Anselmetti, G.C., Osteoplasty: percutaneous bone cement injection beyond the spine. Semin Interv Radiol 27:2 (2010), 199–208.
93. [93] Cazzato, R.L., Buy, X., Eker, O., Fabre, T., Palussiere, J., Percutaneous long bone cementoplasty of the limbs: experience with fifty-one non-surgical patients. Eur Radiol 24:12 (2014), 3059–3068.
94. [94] Deschamps, F., Farouil, G., Hakime, A., Teriitehau, C., Barah, A., de Baere, T., Percutaneous stabilization of impending pathological fracture of the proximal femur. Cardiovasc Interv Radiol 35:6 (2012), 1428–1432.
95. [95] Deschamps, F., Farouil, G., Hakime, A., Barah, A., Guiu, B., Teriitehau, C., et al. Cementoplasty of metastases of the proximal femur: is it a safe palliative option?. J Vasc Interv Radiol 23:10 (2012), 1311–1316.
96. [96] Munk, P.L., Murphy, K.J., Gangi, A., Liu, D.M., Fire and ice: percutaneous ablative therapies and cement injection in management of metastatic disease of the spine. Semin Musculoskelet Radiol 15:2 (2011), 125–134.
97. [97] Deandreis, D., Leboulleux, S., Dromain, C., Auperin, A., Coulot, J., Lumbroso, J., et al. Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation. Radiology 258:1 (2011), 270–276.
98. [98] Hakimé, A., Hines-Peralta, A., Peddi, H., Atkins, M.B., Sukhatme, V.P., Signoretti, S., et al. Combination of radiofrequency ablation with antiangiogenics therapy for tumor ablation efficacy: study in mice. Radiology 244 (2007), 464–470.
99. [99] Erinjeri, J.P., Thomas, C.T., Samoilia, A., Fleisher, M., Gonen, M., Sofocleous, C.T., et al. Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10. J Vasc Interv Radiol 24:8 (2013), 1105–1112.
100. [100] Alteber, Z., Azulay, M., Cafri, G., Vadai, E., Tzehoval, E., Eisenbach, L., Cryoimmunotherapy with local co-administration of ex vivo generated dendritic cells and CpG-ODN immune adjuvant, elicits a specific antitumor immunity. Cancer Immunol Immunother 63:4 (2014), 369–380.
101. [101] Goere, D., Benhaim, L., Bonnet, S., Malka, D., Faron, M., Elias, D., et al. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. Ann Surg 257:1 (2013), 114–120.
102. [102] Goere, D., Deshaies, I., de Baere, T., Boige, V., Malka, D., Dumont, F., et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg 251:4 (2010), 686–691.